Beyond semaglutide and tirzepatide, where might we find the next GLP 1 based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of cagrilintide + semaglutide and CagriSema in Clinical Trials: What Patients Should Know Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link Recent advances in peptide based therapies for obesity and type 2 diabetes ScienceDirect Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide